Open AccessToxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non‐small cell lung cancer
Author(s) -
Huang JiJie,
Ma ShuXiang,
Hou Xue,
Wang Zhao,
Zeng YinDuo,
Qin Tao,
Dinglin XiaoXiao,
Chen LiKun
Publication year - 2015
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.5732/cjc.014.10151
Subject(s) - gefitinib , medicine , toxic epidermal necrolysis , pemetrexed , lung cancer , epidermal growth factor receptor , rash , oncology , erlotinib , chemotherapy , regimen , dermatology , cancer , cancer research , cisplatin
Abstract Toxic epidermal necrolysis (TEN) is a rare acute life‐threatening mucocutaneous disorder that is mostly drug‐related (80%–95%). It is clinically characterized as a widespread sloughing of the skin and mucosa. AP regimen (pemetrexed plus cisplatin) has been the preferred first‐line chemotherapy for metastatic non‐squamous non‐small cell lung cancer (NSCLC). Gefitinib, a small‐molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has already been recommended as a first‐line treatment in EGFR ‐mutant metastatic NSCLC. We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42‐year‐old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. On the 21st day after administration of the first cycle of AP regimen and the 8th day after the initiation of gefitinib treatment, she developed an acne‐like rash, oral ulcer, and conjunctivitis, which later became blisters and ultimately denuded. The characteristic clinical courses were decisive for the diagnosis of TEN. Treatment with systemic steroids and immunoglobulin as well as supportive treatment led to an improvement of her general condition and a remarkable recovery.